Comparative Study of Sexual Side Effects in Female Patients With Schizophrenia Receiving Risperidone or Olanzapine

P. N. Suresh Kumar, MD, DNB, MRCPsych, PhD^a; N. A. Uvais, MBBS, DPM^a; M. K. Radhika, MBBS, DPM^b; Rohith Suresh, MBBS^c

Prim Care Companion CNS Disord 2021;23(4):20m02835

ABSTRACT

Objective: To determine the prevalence of sexual dysfunction in female patients with schizophrenia receiving olanzapine or risperidone and to understand its relationship with other psychosocial variables.

Methods: This cross-sectional descriptive study evaluated 57 female stabilized schizophrenia outpatients receiving risperidone (n = 28) or olanzapine (n = 29) in the psychiatric departments of a tertiary care hospital in South India from January to May 2019. Sexual dysfunction was assessed with the Changes in Sexual Functioning Questionnaire, severity of psychosis with the Brief Psychiatric Rating Scale, and level of improvement with the Clinical Global Impressions–Improvement and Severity scales.

Results: Among the subjects, 93% of women receiving risperidone experienced sexual dysfunction compared to 83% in the olanzapine group. Sexual responses such as pleasure, frequency of sexual contacts, desire, arousal, and orgasm were significantly low in both drug groups (P < .05). Logistic regression of sexual dysfunction as dependent variable with other important variables found no significant relationship.

Conclusions: This study suggests that sexual dysfunction is an important undetected problem in the majority of female schizophrenia patients. Risperidone was associated with more sexual dysfunction. Sexual dysfunction is an understudied yet important consideration in the treatment of schizophrenia.

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (20)

Uçok A, Incesu C, Aker T, et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry. 2007;22(5):328–333. PubMed CrossRef
Mendrek A, Stip E. Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev Neurother. 2011;11(7):951–959. PubMed CrossRef
Costa AM, Lima MS, Mari JdeJ. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006;124(5):291–297. PubMed CrossRef
Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130–140. PubMed CrossRef
Nagaraj AK, Nizamie HS, Akhtar S, et al. A comparative study of sexual dysfunction due to typical and atypical antipsychotics in remitted bipolar I disorder. Indian J Psychiatry. 2004;46(3):261–266. PubMed
Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res. 2006;86(1–3):244–250. PubMed CrossRef
Hocaoglu C, Celik FH, Kandemir G, et al. Sexual dysfunction in outpatients with schizophrenia in Turkey: a cross-sectional study. Shanghai Jingshen Yixue. 2014;26(6):347–356. PubMed
Lodha P, Sousa AD. Female sexual dysfunction and schizophrenia: a clinical review. J Psychosexual Health. 2020;2(1):44–55. CrossRef
Shetageri VN, Bhogale GS, Patil NM, et al. Sexual dysfunction among females receiving psychotropic medication: a hospital-based cross-sectional study. Indian J Psychol Med. 2016;38(5):447–454. PubMed CrossRef
Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry. 2009;51(4):265–271. PubMed CrossRef
Kumar SVS, Sinha VK. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian J Psychiatry. 2015;57(4):386–391. PubMed CrossRef
American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731–745. PubMed
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799–812. CrossRef
Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: US Department of Health, Education, and Welfare; 1976.
Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32(4):315–326. PubMed CrossRef
Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55–68. PubMed
Howes OD, Wheeler MJ, Pilowsky LS, et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007;68(3):361–367. PubMed CrossRef
Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry. 1995;56(4):137–141. PubMed
Liu-Seifert H, Kinon BJ, Tennant CJ, et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat. 2009;5:47–54. PubMed CrossRef